Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

To investigate the potential association between early tirofiban treatment and N-terminal pro-B-type natriuretic peptide (NT-proBNP) level after primary percutaneous coronary intervention (PCI).

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Nine hundred and eighty four ST-elevation myocardial infarction (STEMI) patients undergoing primary PCI were randomized to either pre-hospital tirofiban administration or placebo.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the BNP (Nesiritide) group a baseline to be compared against.

NT-proBNP levels were evaluated on admission before angiography (baseline) and 18-96 hr after PCI.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Emergency Medical Services, Fibrinolytic Agents, Natriuretic Peptide, Brain, Peptide Fragments, Percutaneous Coronary Intervention and Platelet Aggregation Inhibitors.

Author keywords: NT-proBNP, STEMI, glycoprotein IIb/IIIa inhibitors and tirofiban.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.